MedTrace Logo

Randomized Study of Maintenance Therapy With MGN1703 in Patients With SCLC

NCT02200081 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 103

Last updated 2018-11-15

No results posted yet for this study

Summary

Evaluation of efficacy and safety of MGN1703 administered twice weekly subcutaneously (SC) as maintenance treatment in patients with extensive disease small cell lung cancer (SCLC) who achieved at least a partial response (PR) following platinum-based first-line therapy.

Conditions

Interventions

DRUG

MGN1703

OTHER

Standard of care

Usual Standard of Care according to local investigators practise, e.g. Treatment break continous treatment and other

Sponsors & Collaborators

  • Mologen AG

    lead INDUSTRY

Principal Investigators

  • Veerle Surmont, MD · University Hospital Ghent, Belgium 9000

  • Georg Pall, MD · Medizinische Universität Innsbruck, Innere Medizin, Hämatologie und Onkologie

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-03-31
Primary Completion
2016-11-30
Completion
2017-10-05

Countries

  • Austria
  • Belgium
  • Germany
  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02200081 on ClinicalTrials.gov